Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study | Synapse
August 20, 2025Open Access
Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Key Points
Changes in tumor fraction are significant predictors of clinical benefit from immune checkpoint inhibitors.
The study highlights the importance of methylation in assessing treatment outcomes, supporting personalized therapies.
Data was collected from the RADIOHEAD study focused on patient samples passing specific quality control metrics.
Findings suggest that monitoring ctDNA could enhance treatment strategies for cancer patients using immune therapy.
Abstract
Strobe diagram showing inclusion and exclusion for patient samples from the RADIOHEAD study in which successful samples passed all QC metrics and delivered a TF result. Chemo, chemotherapy.